Analysis of device therapies (Table 1; Supplemental Table
2)
The proportion of patients with mixed CMP receiving device therapies
(34.2%) and device shocks (23.6%) was intermediate between ICM (device
therapies 41.1%; device shocks 27.2%) and NICM (device therapies
29.1%; device shocks 18.4%). These differences were not significant
between mixed CMP and the other groups. Among the patients receiving
device shocks, the distribution of appropriate and inappropriate shocks
was comparable between all the 3 groups. The minimum VT cycle length
recorded in patients with mixed CMP (281.6 ± 43.1ms) was comparable to
that in ICM (282.5 ± 44ms; p=0.9) in ICM and lesser than in NICM (297.7
± 48.7ms; p=0.1).